Niraparib

Brand name:
Zejula
IUPAC:
2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
FDA approval:
Yes
Usage:
Niraparib is a once daily oral medication, which is mostly used in the treatment of ovarian cancers. It is also used in treatment of fallopian tube, or primary peritoneal cancers.1
- 1 TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about
Mechanism:
Niraparib works as a by inhibiting an enzym called poly ADP ribose polymerase (PARP). This process allows for the destruction of cancerous cell DNA, which in turns leads to apoptosis.1
- 1 TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about